There are currently 6 active clinical trials seeking participants for Hypercholesterolemia research studies. The states with the highest number of trials for Hypercholesterolemia participants are Florida, California, Texas and Ohio.
Causes and Natural History of Dyslipidemias
Recruiting
This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides, are carried in the blood in particles called lipoproteins. These particles are involved in causing blood vessel diseases that can lead to conditions like atherosclerosis (hardening of the arteries) or heart attack. Participants will undergo accepted medical tests and procedures to evaluate their condition. Most of the test results are he... Read More
Gender:
ALL
Ages:
Between 2 years and 100 years
Trial Updated:
01/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hypercholesterolemia, Atherosclerosis
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
Recruiting
This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2025
Locations: Alliance for Multispecialty Research, LLC ( Site 0027), Daphne, Alabama +197 locations
Conditions: Hypercholesterolemia
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Recruiting
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) an... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
08/06/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Recruiting
Cardiovascular disease (CVD) is the leading cause of death in the US general population. Although CVD mortality rates declined for both Black and White populations during the past two decades, they are still higher in Black adults than White adults. There are also persistent disparities in CVD risk factors with higher prevalence of obesity, hypertension, and diabetes in Black compared to White populations. In addition, CVD and risk factors are more prevalent in the residents of Louisiana compare... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/01/2024
Locations: Tulane University, New Orleans, Louisiana
Conditions: Cardiovascular Diseases, Hypertension, Diabetes, Hypercholesterolemia
Study of Awareness and Detection of Familial Hypercholesterolemia
Recruiting
The CASCADE-FH Registry is a national, multi-center initiative that will track the therapy, clinical outcomes, and patient-reported outcomes over time. The registry represents a collaboration between The Familial Hypercholesterolemia Foundation, the Duke Clinical Research Institute, lipid specialists, cardiologists, primary care providers, quality improvement personnel, and patients, all aiming to increase FH awareness, promote optimal disease management, and improve FH outcomes.
Gender:
All
Ages:
All
Trial Updated:
11/21/2023
Locations: Stanford Center for Inherited Cardiovascular Diseases, Palo Alto, California
Conditions: Hypercholesterolemia
A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing
Recruiting
Multiple-dose study to measure PK, PD and safety of bempedoic acid in pediatric patients 6 to 17 years of age with HeFH.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
08/08/2023
Locations: Smidt Heart Institute at Cedars-Sinai, Los Angeles, California +19 locations
Conditions: Hypercholesterolemia